Brokerages Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Price Target at $22.80

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have been given a consensus rating of "Buy" by the six research firms that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $22.80.

LXEO has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and set a $23.00 price target on shares of Lexeo Therapeutics in a report on Wednesday, March 26th. Chardan Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, March 25th. Leerink Partners decreased their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating for the company in a research note on Monday, March 24th. Finally, Royal Bank of Canada lowered their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a report on Tuesday, March 25th.

Institutional Trading of Lexeo Therapeutics

A number of large investors have recently made changes to their positions in the company. Allostery Investments LP acquired a new position in Lexeo Therapeutics during the fourth quarter worth approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at $46,000. BNP Paribas Financial Markets increased its holdings in shares of Lexeo Therapeutics by 184.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock valued at $50,000 after acquiring an additional 3,591 shares during the period. Price T Rowe Associates Inc. MD purchased a new stake in Lexeo Therapeutics in the 4th quarter valued at $69,000. Finally, SG Americas Securities LLC acquired a new stake in Lexeo Therapeutics during the 4th quarter worth $72,000. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Stock Down 11.4 %

Shares of NASDAQ LXEO traded down $0.30 during mid-day trading on Wednesday, hitting $2.34. The company had a trading volume of 542,954 shares, compared to its average volume of 354,733. The company has a market capitalization of $77.68 million, a PE ratio of -0.74 and a beta of 1.52. The business's 50-day simple moving average is $3.82 and its 200 day simple moving average is $6.29. Lexeo Therapeutics has a 1-year low of $2.27 and a 1-year high of $19.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its quarterly earnings results on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.87) by $0.09. On average, analysts predict that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.